Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focused on muscle diseases, has granted equity-based inducement awards to 3 new non-executive employees. The awards include 84,250 stock options with an exercise price of $14.26 per share and 5,000 restricted stock units (RSUs).
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments starting July 31, 2025. These awards were granted under the company's 2024 Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), una società biofarmaceutica specializzata nelle malattie muscolari, ha assegnato premi azionari a 3 nuovi dipendenti non esecutivi. Gli incentivi comprendono 84.250 opzioni su azioni con un prezzo di esercizio di 14,26 $ per azione e 5.000 unità azionarie vincolate (RSU).
Le opzioni su azioni matureranno in 4 anni, con il 25% che matura dopo un anno e il resto che matura mensilmente. Le RSU matureranno in quattro rate annuali uguali a partire dal 31 luglio 2025. Questi premi sono stati concessi nell'ambito del Piano di Incentivi Azionari di Induzione 2024 della società, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), una empresa biofarmacéutica centrada en enfermedades musculares, ha otorgado premios basados en acciones a 3 nuevos empleados no ejecutivos. Los premios incluyen 84,250 opciones sobre acciones con un precio de ejercicio de $14.26 por acción y 5,000 unidades restringidas de acciones (RSUs).
Las opciones sobre acciones se consolidarán en 4 años, con un 25% consolidado después de un año y el resto consolidándose mensualmente. Las RSUs se consolidarán en cuatro pagos anuales iguales a partir del 31 de julio de 2025. Estos premios se otorgaron bajo el Plan de Incentivos de Capital por Inducción 2024 de la empresa, en cumplimiento con la Norma de Listado Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX)는 근육 질환에 중점을 둔 생명공학 제약 회사로, 3명의 신규 비임원 직원에게 주식 기반 유인 보상을 부여했습니다. 보상에는 84,250주의 스톡 옵션이 포함되며, 행사가격은 주당 14.26달러이고 5,000주의 제한 주식 단위(RSU)도 포함됩니다.
스톡 옵션은 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 부여되고 나머지는 매월 부여됩니다. RSU는 2025년 7월 31일부터 시작하여 4년에 걸쳐 연간 동일한 비율로 부여됩니다. 이 보상은 회사의 2024년 유인 주식 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 부여되었습니다.
Edgewise Therapeutics (NASDAQ : EWTX), une société biopharmaceutique spécialisée dans les maladies musculaires, a accordé des primes incitatives basées sur des actions à 3 nouveaux employés non cadres. Ces primes comprennent 84 250 options d'achat d'actions avec un prix d'exercice de 14,26 $ par action et 5 000 unités d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une période de 4 ans, avec 25 % acquis après un an et le reste acquis mensuellement. Les RSU seront acquises en quatre versements annuels égaux à partir du 31 juillet 2025. Ces primes ont été accordées dans le cadre du Plan d'Incitation en Actions 2024 de la société, conformément à la règle de cotation Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), ein biopharmazeutisches Unternehmen mit Fokus auf Muskelerkrankungen, hat aktienbasierte Anreizprämien an 3 neue nicht-exekutive Mitarbeiter vergeben. Die Prämien umfassen 84.250 Aktienoptionen mit einem Ausübungspreis von 14,26 $ pro Aktie sowie 5.000 Restricted Stock Units (RSUs).
Die Aktienoptionen werden über 4 Jahre unverfallbar, wobei 25 % nach einem Jahr und der Rest monatlich unverfallbar werden. Die RSUs werden in vier gleichen jährlichen Tranchen ab dem 31. Juli 2025 unverfallbar. Diese Prämien wurden im Rahmen des Inducement Equity Incentive Plans 2024 des Unternehmens gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
Each inducement stock option has an exercise price of
Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of July 31, 2025, subject to the employee's continued service.
Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302523500.html
SOURCE Edgewise Therapeutics
FAQ
What inducement grants did Edgewise Therapeutics (EWTX) announce in August 2025?
What is the vesting schedule for EWTX's 2025 inducement stock options?
How will the RSUs granted by Edgewise Therapeutics in 2025 vest?
Under what authority did Edgewise Therapeutics grant these inducement awards?
